Key result
Verapamil shows no benefit over placebo for 6-month mortality in acute myocardial infarction.
Why the study?
The efficacy of verapamil compared with placebo in patients under 75 years with acute myocardial infarction was evaluated.
Does verapamil reduce mortality and reinfarction in patients with acute myocardial infarction?
Population
1436 patients under 75 years with confirmed AMI in Danish CCUs
Comparison
Verapamil 0.1 mg/kg i.v. plus 120 mg oral followed by 120 mg t.i.d. vs matched placebo
Design
Double-blind randomized controlled trial in 16 Danish internal medicine departments
Follow-up
12 months
Loading...
Early verapamil after suspected AMI showed no mortality or reinfarction benefit; leaves open optimal timing and subgroup selection for post-MI calcium antagonists.
RCT (n=1,436)
Double-blind
Yes
Does verapamil reduce mortality and reinfarction in patients with acute myocardial infarction?
Absolute Event Rate: 12.8% vs 13.9%
p-value: p=NS
Verapamil administration in the acute phase of myocardial infarction does not significantly improve 6-month or 12-month survival or reduce reinfarction rates.
A 1984 study conducted an RCT in Acute myocardial infarction (AMI) (n=1,436). Verapamil vs. Placebo was evaluated on Mortality at 6 months (p=NS). Verapamil treatment for 6 months did not significantly reduce mortality at 6 months compared to placebo in patients with acute myocardial infarction (12.8% vs 13.9%; NS).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: